By Professor Marina Pajic

Other

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Data from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.c.8179124

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761555

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761552

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761549

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761546

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761543

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Fig. S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761540

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761537

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S10 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761534

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S11 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761531

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761528

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761525

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761522

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761519

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761516

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S7 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761513

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S8 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761510

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, Supplementary Table S9 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma, http://dx.doi.org/10.1158/1535-7163.30761507

Back to profile page